Morgan Stanley lowered the firm’s price target on UnitedHealth (UNH) to $342 from $374 and keeps an Overweight rating on the shares. New leadership will likely set a highly conservative bar for 2025 and 2026, reflecting continued Optum woes, likely stepped up investments, but also some element of Medicare Advantage margin recovery in 2026, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- Moderately bullish activity in UnitedHealth with shares up 0.27%
- Barclays Cuts UnitedHealth Stock (UNH) Price Target as Q2 Earnings Loom
- “Not Out of the Woods” as Top Analyst Cuts UnitedHealth Stock’s (UNH) Price Target
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- UnitedHealth Stock (UNH) Sinks as DOJ Criminal Probe into Medicare Fraud Deepens